Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Raising Price Target After ASCO Meeting Review
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Seattle Genetics (NASDAQ: SGEN) price target of $25.00 (from $20.00).
Analyst, Alan ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Alan ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
